首页> 美国卫生研究院文献>Journal of Virology >Targeted Deletion of Regions Rich in Immune-Evasive Genes from the Cytomegalovirus Genome as a Novel Vaccine Strategy
【2h】

Targeted Deletion of Regions Rich in Immune-Evasive Genes from the Cytomegalovirus Genome as a Novel Vaccine Strategy

机译:有针对性地删除巨细胞病毒基因组中的免疫逃逸基因丰富的区域作为一种新型疫苗策略

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Human cytomegalovirus (CMV), a ubiquitous human pathogen, is a leading cause of congenital infections and represents a serious health risk for the immunosuppressed patient. A vaccine against CMV is currently not available. CMV is characterized by its large genome and by multiple genes modulating the immunity of the host, which cluster predominantly at genome termini. Here, we tested whether the deletion of gene blocks rich in immunomodulatory genes could be used as a novel concept in the generation of immunogenic but avirulent, herpesvirus vaccines. To generate an experimental CMV vaccine, we selectively deleted 32 genes from the mouse cytomegalovirus (MCMV) genome. The resulting mutant grew to titers similar to that of wild-type MCMV in vitro. In vivo, the mutant was 10,000-fold attenuated and well tolerated, even by highly susceptible mice deficient for B, T, and NK cells or for the interferon type I receptor. Equally relevant for safety concerns, immune suppression did not lead to the mutant's reactivation from latency. Immunization with the replication-competent mutant, but not with inactivated virus, resulted in protective immunity, which increased over time. Vaccination induced MCMV-specific antibodies and a strong T-cell response. We propose that a targeted and rational approach can improve future herpesvirus vaccines and vaccine vectors.
机译:人类巨细胞病毒(CMV)是一种普遍存在的人类病原体,是先天性感染的主要原因,并且对免疫抑制患者构成严重的健康风险。目前尚无抗CMV的疫苗。 CMV的特征在于其庞大的基因组和调节宿主免疫力的多个基因,这些基因主要聚集在基因组末端。在这里,我们测试了是否可以将富含免疫调节基因的基因区块删除作为产生免疫原性但无毒的疱疹病毒疫苗的新概念。为了生成实验性CMV疫苗,我们从小鼠巨细胞病毒(MCMV)基因组中选择性删除了32个基因。所得的突变体在体外生长至与野生型MCMV相似的滴度。在体内,即使是缺乏B,T和NK细胞或I型干扰素受体的高度易感小鼠,该突变体的减毒能力也达到10,000倍,并且具有良好的耐受性。与安全性考虑同样重要的是,免疫抑制并未导致突变体从潜伏期重新激活。具有复制能力的突变体(但未灭活的病毒)的免疫导致保护性免疫,其随时间增加。疫苗诱导MCMV特异性抗体和强烈的T细胞反应。我们建议有针对性和合理的方法可以改善未来的疱疹病毒疫苗和疫苗载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号